The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO [Yahoo! Finance News]
NanoViricides, Inc. (NNVC)
NASDAQ:AMEX Investor Relations:
nanoviricides.com/investorinfo.html
Company Research
Source: Yahoo! Finance News
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks Biotech Stocks Hitting 52-week highs on Jan. 30) Down In The Dumps Biotech Stocks Hitting 52-week lows on Jan. 30) Stocks In Focus Nanoviricides Working On Wuhan Coronavirus Treatment NanoViricides Inc NNVC Wuhan coronavirus. "Our platform technology enables possibly the most rapid pathway for new drug development against viral diseases," said Anil Diwan, President and Executive Chairman of Nanoviricides. The stock jumped 41.67% to $17 in after-hours trading. Earnings Amgen, Inc.'s AMGN For the full-year, Amgen guided to revenues of $25 billion to $25.6 billion and non-GAAP EPS in the range of $14.85-$15.60. Analysts estimate EPS of $16.14 on revenues of $25.49 billion. View more earnings on IBB Vertex Pharmaceuticals Incorporated VRTX For the full year, the company guided product revenues of $5.1 billion to $5.3 billion. Analyst estimat
Show less
Read more
Impact Snapshot
Event Time:
NNVC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NNVC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NNVC alerts
High impacting NanoViricides, Inc. news events
Weekly update
A roundup of the hottest topics
NNVC
News
- NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape [Yahoo! Finance]Yahoo! Finance
- NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to EscapeAccesswire
- NanoViricides, Inc. (NYSE: NNVC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID [Yahoo! Finance]Yahoo! Finance
- NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVIDAccesswire
NNVC
Sec Filings
- 12/12/24 - Form 8-K
- 11/14/24 - Form 10-Q
- 10/15/24 - Form DEF
- NNVC's page on the SEC website